Literature DB >> 18470275

Maximizing the treatment of overactive bladder in the elderly.

Scott A Macdiarmid1.   

Abstract

Overactive bladder syndrome affects millions of elderly people in the United States and is equally prevalent in men and women. Its impact on quality of life can be devastating, especially to elderly patients with other medical comorbidities. In order to maximize care, health care providers must be able to make the correct diagnosis and have a working knowledge of available therapies. Data exist supporting the efficacy and safety of nonpharmacologic and pharmacologic therapies.

Entities:  

Keywords:  Antimuscarinic agents; Behavioral therapy; Elderly; Incontinence; Overactive bladder syndrome

Year:  2008        PMID： 18470275      PMCID： PMC2312344     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  19 in total

Review 1.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

2.  Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.

Authors:  Jenelle Foote; Karin Glavind; Georg Kralidis; Jean-Jacques Wyndaele
Journal:  Eur Urol       Date:  2005-09       Impact factor: 20.096

Review 3.  The overactive bladder: an overview for primary care health providers.

Authors:  A J Wein; E S Rovner
Journal:  Int J Fertil Womens Med       Date:  1999 Mar-Apr

Review 4.  Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder.

Authors:  W F McGhan
Journal:  Am J Manag Care       Date:  2001-03       Impact factor: 2.229

5.  Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group.

Authors:  J S Brown; E Vittinghoff; J F Wyman; K L Stone; M C Nevitt; K E Ensrud; D Grady
Journal:  J Am Geriatr Soc       Date:  2000-07       Impact factor: 5.562

Review 6.  Comorbidities associated with overactive bladder.

Authors:  J S Brown; W F McGhan; S Chokroverty
Journal:  Am J Manag Care       Date:  2000-07       Impact factor: 2.229

7.  Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.

Authors:  Norman R Zinner; Anders Mattiasson; Stuart L Stanton
Journal:  J Am Geriatr Soc       Date:  2002-05       Impact factor: 5.562

8.  Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.

Authors:  Roger R Dmochowski; G Willy Davila; Norman R Zinner; Marc C Gittelman; Daniel R Saltzstein; Sydney Lyttle; Steven W Sanders
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

9.  Urinary incontinence in elderly nursing home patients.

Authors:  J G Ouslander; R L Kane; I B Abrass
Journal:  JAMA       Date:  1982-09-10       Impact factor: 56.272

10.  Estimated economic costs of overactive bladder in the United States.

Authors:  Teh-Wei Hu; Todd H Wagner; Judith D Bentkover; Kristi LeBlanc; Amy Piancentini; Walter F Stewart; Ron Corey; Steve Z Zhou; Timothy L Hunt
Journal:  Urology       Date:  2003-06       Impact factor: 2.649
View more
  10 in total

Review 1.  Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.

Authors:  Scott Martin Vouri; Clark D Kebodeaux; Paul M Stranges; Besu F Teshome
Journal:  Arch Gerontol Geriatr       Date:  2016-11-14       Impact factor: 3.250

Review 2.  Perspectives on overactive bladder in the elderly population.

Authors:  Masaki Yoshida
Journal:  World J Urol       Date:  2009-11-11       Impact factor: 4.226

3.  Use of onabotulinumtoxinA for overactive bladder with concomitant warfarin.

Authors:  Golden L Peters; Scott Martin Vouri
Journal:  Consult Pharm       Date:  2014-07

4.  A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial.

Authors:  Michael A Weber; Christopher R Chapple; Christian Gratzke; Sender Herschorn; Dudley Robinson; Jeffrey M Frankel; Arwin M Ridder; Matthias Stoelzel; Asha Paireddy; Robert van Maanen; William B White
Journal:  Blood Press Monit       Date:  2018-06       Impact factor: 1.444

5.  Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.

Authors:  Shelagh M Szabo; Katherine Gooch; Carol Schermer; David Walker; G Lozano-Ortega; Basia Rogula; Alison Deighton; Edward Vonesh; Noll Campbell
Journal:  BMJ Open       Date:  2019-05-05       Impact factor: 2.692

6.  Overactive bladder in an integrated delivery system: a longitudinal cohort study.

Authors:  Jeffrey A Linder; Joel S Weissman; Harry Reyes Nieva; Stuart Lipsitz; R Sterling Haring; Julie DeAngelis; Rita M Kristy; Kevin R Loughlin
Journal:  BMC Health Serv Res       Date:  2020-05-20       Impact factor: 2.655

7.  The role of prescription drugs in female overactive bladder syndrome-A population-wide cohort study.

Authors:  Wolfgang Umek; Andreas Gleiss; Barbara Bodner-Adler; Berthold Reichardt; Christoph Rinner; Georg Heinze
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-12-05       Impact factor: 2.890

8.  The Costs and Healthcare Resource Utilization Associated with Anticholinergic Burden in Long-Stay Nursing Home Residents with Overactive Bladder in the US.

Authors:  Satabdi Chatterjee; David Walker; Tomomi Kimura; Rajender R Aparasu
Journal:  Pharmacoecon Open       Date:  2021-07-13

9.  Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.

Authors:  V W Nitti; V Khullar; P van Kerrebroeck; S Herschorn; J Cambronero; J C Angulo; M B Blauwet; C Dorrepaal; E Siddiqui; N E Martin
Journal:  Int J Clin Pract       Date:  2013-05-21       Impact factor: 2.503

10.  Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System.

Authors:  Greta Lozano-Ortega; Daniel B Ng; Shelagh M Szabo; Alison M Deighton; Bruno Riveros; Anne Guttschow; Katherine L Gooch; Cristiano M Gomes
Journal:  Adv Ther       Date:  2020-04-15       Impact factor: 3.845
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.